Skip to main content

US Regulators Clear GE Healthcare's $580M Purchase of Clarient

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – The Federal Trade Commission has cleared the way for GE Healthcare's purchase of molecular diagnostics and imaging firm Clarient.

The FTC this week granted GE Healthcare early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvement Act of 1976, removing antitrust barriers in the US to the cash deal, estimated at $570 million to $580 million.

The proposed acquisition was announced in October. At the time, GE Healthcare said that its diagnostic imaging capabilities combined with Clarient's technologies would hasten development of new integrated tools for diagnosing and characterizing cancer. It added that the global market for cancer-profiling products and services is forecast to increase to $47 million by 2015 from $15 million in 2009.

GE Healthcare has said the deal is expected to close later this year or early in 2011.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.